{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:46:25Z","timestamp":1761518785629},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[1993,10,1]],"date-time":"1993-10-01T00:00:00Z","timestamp":749433600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[1993,10]]},"DOI":"10.1007\/bf01320908","type":"journal-article","created":{"date-parts":[[2005,3,26]],"date-time":"2005-03-26T19:28:15Z","timestamp":1111865295000},"page":"237-241","source":"Crossref","is-referenced-by-count":22,"title":["Pamidronate is effective for paget's disease of bone refractory to conventional therapy"],"prefix":"10.1007","volume":"53","author":[{"given":"Sunil J.","family":"Wimalawansa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjan D.","family":"Gunasekera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/bmj.280.6222.1105","volume":"280","author":"DJP Barker","year":"1980","unstructured":"Barker DJP, Chamberlain AT, Guyer PB, Gardner MJ (1980) Paget's disease of bone: the Lancashire focus. Br Med J 280:1105?1107","journal-title":"Br Med J"},{"key":"CR2","volume-title":"Paget's disease of bone","author":"RC Hamdy","year":"1981","unstructured":"Hamdy RC (1981) Paget's disease of bone. Praeger Press, New York"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"8791","DOI":"10.1016\/0221-8747(80)90003-X","volume":"2","author":"IM Evans","year":"1980","unstructured":"Evans IM, Banks L, Doyle FH (1980) Paget's disease of bone. The effect of stopping long-term human calcitonin and recommendations for future treatment. Metab Bone Dis Rel Res 2:8791","journal-title":"Metab Bone Dis Rel Res"},{"key":"CR4","first-page":"121","volume-title":"Advances in bone regulatory factors: morphology, biochemistry, physiology and pharmacology","author":"SJ Wimalawansa","year":"1989","unstructured":"Wimalawansa SJ (1989) Calcitonin: molecular biology, physiology, pathophysiology and its therapeutic uses. In: Pecile A, Bernard B (eds) Advances in bone regulatory factors: morphology, biochemistry, physiology and pharmacology. Plenum Press, England, pp 121?160"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0140-6736(67)90897-5","volume":"ii","author":"OLM Bijvoet","year":"1967","unstructured":"Bijvoet OLM, Sluys Veer JVO, Jansen AP (1967) Thyrocalcitonin in Paget's disease. Lancet ii:471?472","journal-title":"Lancet"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/0002-9343(74)90815-8","volume":"56","author":"J DeRose","year":"1974","unstructured":"DeRose J, Singer FR, Avramides A, Flores A, Dziadiw R, Baker RK, Wallach S (1974) Response of Paget's disease to porcine and salmon calcitonin. Am J Med 56:858?866","journal-title":"Am J Med"},{"key":"CR7","first-page":"78","volume":"127","author":"A Avramides","year":"1977","unstructured":"Avramides A (1977) Salmon and porcine calcitonin in the treatment of Paget's disease of bone. Clin Orthop 127:78?85","journal-title":"Clin Orthop"},{"key":"CR8","first-page":"C18","volume-title":"Therapeutic drugs: a clinical pharmacopia","author":"SJ Wimalawansa","year":"1991","unstructured":"Wimalawansa SJ, MacIntyre I (1991) Calcitonin. In: Dollery CT (ed) Therapeutic drugs: a clinical pharmacopia. Churchill Livingstone, UK, pp C18-C22"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1172\/JCI107140","volume":"51","author":"JG Haddad Jr","year":"1972","unstructured":"Haddad JG, Jr, Caldwell JG (1972) Calcitonin resistance: clinical and immunological studies in subjects with Paget's disease of bone treated with porcine and salmon calcitonins. J Clin Invest 51:3133?3136","journal-title":"J Clin Invest"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/jbmr.5650070915","volume":"7","author":"SJ Wimalawansa","year":"1992","unstructured":"Wimalawansa SJ, Gunasekera RD, Datta HK (1992) Hypocalcemic actions of amylin amide in human. J Bone Miner Res 7:1113?1116","journal-title":"J Bone Miner Res"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/archinte.1989.00390020105022","volume":"149","author":"S Drake","year":"1989","unstructured":"Drake S, Massie JD, Postlethwaite AE, Palmieri GMO (1989) Pamidronate sodium and calcitonin-resistant Paget's disease: immediate response in a patient. Arch Intern Med 149:401?403","journal-title":"Arch Intern Med"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/art.1780231018","volume":"23","author":"OLM Bijvoet","year":"1980","unstructured":"Bijvoet OLM, Frijlink WB, Jie K (1980) APD in Paget's disease of bone. Arthritis Rheum 23:1193?1204","journal-title":"Arthritis Rheum"},{"key":"CR13","first-page":"319","volume-title":"Bone and mineral research, annual 1","author":"H Fleisch","year":"1983","unstructured":"Fleisch H (1983) Bisphosphonates: mechanism of action and clinical applications. In: Peck WA (ed) Bone and mineral research, annual 1. Excerpta Medica, Amsterdam, pp 319?357"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1445-5994.1984.tb03778.x","volume":"14","author":"TRC Fraser","year":"1984","unstructured":"Fraser TRC, King A, Ibbertson HK (1984) Effective oral treatment of severe Paget's disease of bone with APD (3-amino-1-hydroxypropylidene-1,1-bisphosphonate): a comparison with combined calcitonin and EHDP (1-hydroxyethylidene-1,1-bisphosphonate). Aust NZ J Med 14:811?818","journal-title":"Aust NZ J Med"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/bmj.295.6609.1301","volume":"295","author":"HIJ Harinck","year":"1987","unstructured":"Harinck HIJ, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, Bijvoet OLM (1987) Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J 295:1301?1305","journal-title":"Br Med J"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1136\/jcp.35.8.807","volume":"35","author":"A Hodgkinson","year":"1982","unstructured":"Hodgkinson A, Thompson T (1982) Measurement of the fasting urinary hydroxyproline:creatinine ratio in normal adults and its variation with age and sex. J Clin Pathol 35:807?811","journal-title":"J Clin Pathol"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0009-8981(77)90281-9","volume":"80","author":"KB Whitaker","year":"1977","unstructured":"Whitaker KB, Whitby LG, Moss DW (1977) Activities of bone and liver alkaline phosphatases in serum in health and disease. Clin Chem Acta 80:209?220","journal-title":"Clin Chem Acta"},{"key":"CR18","first-page":"405","volume-title":"Molecular endocrinology","author":"C Nagant de Deuxchaisnes","year":"1979","unstructured":"Nagant de Deuxchaisnes C, Rombouts-Lindemans C, Huaux JP, Dovogelaer JP, Malghem J, Maldague B (1979) Roentgenologic evaluation of the actions of the diphosphonate EHDP and combined therapy (EHDP and calcitonin) in Paget's disease of bone. In: MacIntyre I, Szelke M (eds) Molecular endocrinology. Elsevier\/North Holland, Amsterdam, pp 405?433"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"619","DOI":"10.7326\/0003-4819-96-5-619","volume":"96","author":"SM Krane","year":"1982","unstructured":"Krane SM (1982) Etidronate disodium in the treatment of Paget's disease of bone. Ann Intern Med 96:619?625","journal-title":"Ann Intern Med"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(84)92272-4","volume":"i","author":"BF Boyce","year":"1984","unstructured":"Boyce BF, Smith L, Forgleman I, Johnston E, Ralston SH, Boyle IT (1984) Focal osteomalacia due to low dose diphosphonate therapy in Paget's disease. Lancet i:821?824","journal-title":"Lancet"},{"key":"CR21","first-page":"86","volume":"127","author":"FR Singer","year":"1977","unstructured":"Singer FR (1977) Human calcitonin treatment of Paget's disease of bone. Clin Orthop 127:86?93","journal-title":"Clin Orthop"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/BF00308314","volume":"52","author":"SJ Wimalawansa","year":"1993","unstructured":"Wimalawansa SJ (1993) Long- and short-term side effects and safety of calcitonin in man: a prospective study. Calcif Tissue Int 52:90?93","journal-title":"Calcif Tissue Int"},{"key":"CR23","first-page":"422","volume":"209","author":"JF Obie","year":"1979","unstructured":"Obie JF, Cooper CW (1979) Loss of calcaemic effects of calcitonin and parathyroid hormone infused continuously into rats using the Alzet osmotic minipump. J Pharmacol Exp Ther 209:422?428","journal-title":"J Pharmacol Exp Ther"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1172\/JCI107044","volume":"51","author":"FR Singer","year":"1972","unstructured":"Singer FR, Alfred JP, Neer RM, Krane SM, Potts JT Jr, Bloch KJ (1972) An evaluation of antibodies and clinical resistance to salmon calcitonin. J Clin Invest 51:2331?2336","journal-title":"J Clin Invest"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1002\/art.1780231012","volume":"23","author":"FR Singer","year":"1980","unstructured":"Singer FR, Fredericks RS, Minkin C (1980) Salmon calcitonin therapy for Paget's disease of bone: the problem of acquired clinical resistance. Arth Rheum 23:1148?1154","journal-title":"Arth Rheum"},{"key":"CR26","first-page":"223","volume-title":"Calcitonin, 1984: chemistry, physiology, pharmacology and clinical aspects","author":"JM Zanelli","year":"1985","unstructured":"Zanelli JM, Salmon DM, Azria M, Zanelli GD (1985) A rat model for clinical resistance to chronic treatment with salmon calcitonin: application of quantitative cytochemistry. In: Pecile A (ed) Calcitonin, 1984: chemistry, physiology, pharmacology and clinical aspects. Excerpta Medica, Amsterdam, pp 223?230"},{"key":"CR27","first-page":"285","volume":"34","author":"AH Tashjian Jr","year":"1978","unstructured":"Tashjian AH Jr, Wright DR, Ivey JL, Pont A (1978) Calcitonin binding sites in bone: relationships to biological response and escape. Recent Prog Horm Res 34:285?334","journal-title":"Recent Prog Horm Res"},{"key":"CR28","unstructured":"Ziegler R, Holz G, Raue H, Minne H, Delling G (1976) Therapeutic studies with human calcitonin. In: MacIntyre I (ed) Human calcitonin and Paget's disease. Proc Int Workshop, London, Huber, Vienna, p 167"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/0140-6736(90)90043-5","volume":"i","author":"JA Kanis","year":"1990","unstructured":"Kanis JA, McCloskey EV, Paterson AHG (1990) Use of diphosphonate in hypercalcaemia due to malignancy. Lancet i:170?171","journal-title":"Lancet"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/BF02556671","volume":"41","author":"S Adami","year":"1987","unstructured":"Adami S, Bhalla AK, Dorizzo R, Montesant F, Rosini S, Salvagno G, Locascio V (1987) The acute phase response after bisphosphonate administration. Calcif Tissue Int 41:326?331","journal-title":"Calcif Tissue Int"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01320908.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF01320908\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01320908","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T08:01:06Z","timestamp":1556784066000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF01320908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,10]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1993,10]]}},"alternative-id":["BF01320908"],"URL":"https:\/\/doi.org\/10.1007\/bf01320908","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[1993,10]]}}}